Irinotecan Viatris (Irinotecan Hydrochloride Trihydrate)

The drug is converted inside cells to the active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex. This prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and ultimately cancer cell death.

The specific dose and schedule are determined by the prescribing oncologist based on the patient’s condition, body surface area, and treatment protocol. Dosing is individualized and should follow the prescriber’s instructions.

Safety data in pregnancy and lactation are limited. The product should be avoided in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Irinotecan is a pro‑drug converted to SN‑38, whereas other agents such as topotecan are administered directly. Both share a similar mechanism of stabilising the topoisomerase I‑DNA complex, but differences in pharmacokinetics, toxicity profiles and approved indications may influence the choice of therapy.

The injectable solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Before administration, inspect the vial for particulate matter and ensure the solution is at room temperature if required by the clinical protocol.

Irinotecan Viatris is given as an intravenous infusion, usually over 30 to 90 minutes depending on the regimen. Administration is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring for infusion‑related reactions.

The most serious risks include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhoea or colitis, hepatic toxicity, and rare allergic reactions. Prompt recognition and supportive care are essential to manage these complications.

Patients with known hypersensitivity to irinotecan or any of its excipients, those with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment should not receive the drug. Use is also contraindicated in pregnant women unless absolutely necessary.